FIELD: biotechnology.
SUBSTANCE: invention relates to the area of biotechnology, particularly to a recombinant bispecific antibody selectively binding human beta-1a interferon and capable to neutralise biological activity thereof and binding human ErbB2 receptor. Also disclosed is an isolated DNA fragment encoding the light chain of said antibody. The invention also relates to an antigen-binding fragment of a recombinant bispecific antibody selectively binding human beta-1a interferon and human ErbB2 receptor.
EFFECT: invention allows to obtain new bispecific antibodies with therapeutic potential and to reduce side effects of use of human beta-1a interferon.
4 cl, 7 dwg, 1 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMAN TSLP ANTIBODIES AND USE THEREOF | 2021 |
|
RU2825460C1 |
| HUMANISED NEUTRALIZING ANTIBODY TO HUMAN INTERFERON-BETA | 2019 |
|
RU2737466C1 |
| BISPECIFIC ANTIBODY AGAINST CD3E/BCMA AND ITS USE | 2019 |
|
RU2800164C2 |
| BISPECIFIC ANTIGEN-BINDING CONSTRUCTS AGAINST HER2 | 2014 |
|
RU2737882C2 |
| BISPECIFIC ANTIBODY AGAINST RABIES VIRUS AND ITS APPLICATION | 2019 |
|
RU2764740C1 |
| MULTI-SPECIFIC ANTIBODIES AND METHODS OF THEIR PRODUCTION AND USE | 2018 |
|
RU2811477C2 |
| ANTIBODY AGAINST PLATELET-DERIVED GROWTH FACTOR (PDGF) RECEPTOR AND APPLICATION THEREOF | 2019 |
|
RU2778023C1 |
| TETANUS TOXIN ANTIBODY AND USE THEREOF | 2020 |
|
RU2815280C1 |
| Fab FRAGMENT OF HUMANIZED ANTIBODY AGAINST VEGF AND ITS USE | 2020 |
|
RU2802960C2 |
| ANTIBODIES AGAINST OX40 AND THEIR USE | 2017 |
|
RU2783314C2 |
